CureVac N.V (CVAC): Price and Financial Metrics


CureVac N.V (CVAC): $9.15

-0.23 (-2.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CVAC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CVAC Stock Price Chart Interactive Chart >

Price chart for CVAC

CVAC Price/Volume Stats

Current price $9.15 52-week high $20.49
Prev. close $9.38 52-week low $5.63
Day low $9.10 Volume 6,509,911
Day high $9.45 Avg. volume 1,955,681
50-day MA $8.65 Dividend yield N/A
200-day MA $11.18 Market Cap 1.71B

CureVac N.V (CVAC) Company Bio


CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.(Source:Wikipedia)


CVAC Latest News Stream


Event/Time News Detail
Loading, please wait...

CVAC Latest Social Stream


Loading social stream, please wait...

View Full CVAC Social Stream

Latest CVAC News From Around the Web

Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

CureVac Announces Proposed Public Offering of Common Shares

CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of its common shares in an underwritten public offering.

Yahoo | February 7, 2023

CureVac Welcomes Myriam Mendila as New Chief Development Officer

/ CureVac N.V.

Yahoo | February 1, 2023

Why did CureVac stock slip today? Declining market for COVID vaccines (NASDAQ:CVAC)

CureVac (CVAC) shares dropped ~7% Tuesday likely due to comments Pfizer made earlier in the day that it expects a 64% drop in revenue from its COVID-19 vaccine.

Seeking Alpha | January 31, 2023

EQS-News: CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis

Issuer: CureVac / Key word(s): Patent CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis 31.01.2023 / 14:12 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis

Wallstreet:Online | January 31, 2023

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)

/ CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its inclusion in the second annual "Innovation Momentum: Global Top 100" report by LexisNexis®. Top 100 recognizes companies advancing innovative solutions to address today's challenges and laying the intellectual property foundations for further breakthroughs.

Yahoo | January 31, 2023

Read More 'CVAC' Stories Here

CVAC Price Returns

1-mo -11.68%
3-mo 24.32%
6-mo -32.12%
1-year -49.17%
3-year N/A
5-year N/A
YTD 51.74%
2022 -82.42%
2021 -57.68%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7902 seconds.